Smoking-related changes in DNA methylation and gene expression are associated with cardio-metabolic traits by Maas, S.C.E. et al.
Maas et al. Clin Epigenet          (2020) 12:157  
https://doi.org/10.1186/s13148-020-00951-0
RESEARCH
Smoking-related changes in DNA 
methylation and gene expression are associated 
with cardio-metabolic traits
Silvana C. E. Maas1,2, Michelle M. J. Mens1, Brigitte Kühnel3,4, Joyce B. J. van Meurs5, André G. Uitterlinden1,5, 
Annette Peters3,4,6,7, Holger Prokisch8, Christian Herder9,10,11, Harald Grallert4, Sonja Kunze3,4, 
Melanie Waldenberger3,4,6, Maryam Kavousi1, Manfred Kayser2 and Mohsen Ghanbari1* 
Abstract 
Background: Tobacco smoking is a well-known modifiable risk factor for many chronic diseases, including cardiovas-
cular disease (CVD). One of the proposed underlying mechanism linking smoking to disease is via epigenetic modifi-
cations, which could affect the expression of disease-associated genes. Here, we conducted a three-way association 
study to identify the relationship between smoking-related changes in DNA methylation and gene expression and 
their associations with cardio-metabolic traits.
Results: We selected 2549 CpG sites and 443 gene expression probes associated with current versus never smokers, 
from the largest epigenome-wide association study and transcriptome-wide association study to date. We examined 
three-way associations, including CpG versus gene expression, cardio-metabolic trait versus CpG, and cardio-meta-
bolic trait versus gene expression, in the Rotterdam study. Subsequently, we replicated our findings in The Coopera-
tive Health Research in the Region of Augsburg (KORA) study. After correction for multiple testing, we identified both 
cis- and trans-expression quantitative trait methylation (eQTM) associations in blood. Specifically, we found 1224 
smoking-related CpGs associated with at least one of the 443 gene expression probes, and 200 smoking-related gene 
expression probes to be associated with at least one of the 2549 CpGs. Out of these, 109 CpGs and 27 genes were 
associated with at least one cardio-metabolic trait in the Rotterdam Study. We were able to replicate the associations 
with cardio-metabolic traits of 26 CpGs and 19 genes in the KORA study. Furthermore, we identified a three-way asso-
ciation of triglycerides with two CpGs and two genes (GZMA; CLDND1), and BMI with six CpGs and two genes (PID1; 
LRRN3). Finally, our results revealed the mediation effect of cg03636183 (F2RL3), cg06096336 (PSMD1), cg13708645 
(KDM2B), and cg17287155 (AHRR) within the association between smoking and LRRN3 expression.
Conclusions: Our study indicates that smoking-related changes in DNA methylation and gene expression are associ-
ated with cardio-metabolic risk factors. These findings may provide additional insights into the molecular mechanisms 
linking smoking to the development of CVD.
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Background
Tobacco smoking is a major modifiable risk factor for 
premature death and non-communicable diseases 
worldwide [1]. With almost 18 million deaths in 2017, 
cardiovascular diseases (CVD) account for the largest 
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number of deaths of non-communicable diseases [2]. 
Smoking is also associated with cardio-metabolic traits, 
such as dyslipidemia, hypertension, insulin resist-
ance, and obesity, which are major risk factors leading 
to CVD [3, 4]. Furthermore, persistent smoking has 
an excessive impact on DNA methylation [5–7] and 
gene expression [8–10], which their alterations are 
also linked to cardio-metabolic traits and risk of CVD 
[11–16].
Extensive studies have shown the independent asso-
ciation of smoking with DNA methylation, gene expres-
sion levels, and disease risk. In this context, smoking 
is associated with alteration in DNA methylation lev-
els of several genes related to type 2 diabetes [17] and 
coronary artery disease [18]. Additionally, smoking-
related CpGs have a strong association with all-cause 
and cardiovascular mortality [19]. Nevertheless, much 
less research has investigated smoking-related changes 
in DNA methylation and gene expression concurrently 
and in relation to health outcomes. A recent study iden-
tified a link between smoking-related DNA methylation 
and gene expression changes with metabolic health 
[20]. Their results indicate possible molecular pathways 
in which smoking affects disease development.
In this study, we hypothesized that smoking-related 
modifications in DNA methylation and gene expres-
sion are associated with each other and, additionally, 
with cardio-metabolic traits. Hence, we first deter-
mined three-way associations, including CpGs versus 
gene expression, cardio-metabolic traits versus CpGs, 
cardio-metabolic traits versus gene expression. To this 
end, we selected CpGs and gene expression probes 
associated with current versus never smokers using the 
largest published epigenome-wide association study 
(EWAS) [6] and transcriptome-wide association study 
(TWAS) [8] to date. Next, we used data from the Rot-
terdam Study to test the expression quantitative trait 
methylation (eQTM) association between the selected 
CpGs and gene expression probes. Subsequently, we 
tested the association for these CpGs and genes with 
different cardio-metabolic traits, including lipids, glyce-
mic indices, blood pressure, and obesity-related traits. 
Moreover, we performed mediation analysis to test the 
mediating effect of; (1) DNA methylation in the asso-
ciation between smoking and cardio-metabolic traits, 
(2) gene expression in the association between smoking 
and cardio-metabolic traits, and (3) DNA methylation 
in the association between smoking and expression lev-
els of smoking-related genes. To test the validity of our 
findings, we further replicated our results in an inde-
pendent cohort, The Cooperative Health Research in 
the Region of Augsburg (KORA) study.
Results
An overview of our study design is illustrated in Fig.  1. 
The discovery dataset consisted of 1412 participants 
with DNA methylation data from the two sub-cohorts 
of the Rotterdam study; RS-II and RS-III. Of these, 716 
participants from RS-III had also gene expression data 
[21]. The replication dataset comprises 1727 participants 
with DNA methylation data, of whom 687 also had gene 
expression data, from the KORA study (F4) [22]. Both the 
discovery and replication cohorts consisted of both males 
and females (53.3%) and current, former and never smok-
ers. In the current study, the former and never smokers 
are combined in the non-smoker category (83.6%). Gen-
eral characteristics of the study population are listed in 
Table 1.
Correlation between smoking‑related changes in DNA 
methylation and gene expression
We selected 2623 CpGs previously reported as being sig-
nificantly (P < 1 × 10–7) differentially methylated between 
smokers and never smokers [6]. Of these, 2549 CpGs 
passed the quality control in the Rotterdam Study. Fur-
thermore, we selected 502 gene expression probes that 
were differently expressed between smokers and never 
smokers (FDR < 0.05) and replicated in an independ-
ent dataset as part of the same study [8]. Of these, 443 
gene expression probes passed quality control in the 
Rotterdam Study. Then, we investigated the eQTM asso-
ciations to test the possible impact of smoking-related 
DNA methylation changes on the smoking-related genes, 
or vice versa. To this end, we computed the residuals 
for both the CpGs and gene expression probes. Then, 
we tested the association between all the smoking-
related CpGs with all the smoking-related gene expres-
sion probes. Here, we investigated cis-eQTMs in which 
the CpG regulates transcription of a neighboring gene 
(≤ 250 Kb from each side of the transcription start site). 
Also, we studied the trans-eQTM association in which a 
CpG regulates distant genes located > 250 Kb of the tran-
scription start site [23]. Notably, out of the 2549 smok-
ing-related CpGs, 1224 were associated with at least one 
of the gene expression probes at the significance thresh-
old of P < 4.4 × 10–8 (0.05/443 × 2549). Of the 443 tested 
gene expression probes, 200 probes were significantly 
associated with at least one of the 2549 CpGs, after cor-
recting for multiple testing (Additional file 1: Table  S1). 
The R code to generate the residuals for the CpGs and 
gene expression probes, and for the eQTM analysis are 
included in Additional file 2.
To examine the possible enrichment due to the smok-
ing effect, we further tested if the number of significant 
eQTM associations is higher while using smoking-related 
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CpGs and genes, compared to the number of eQTM 
associations while using randomly selected CpGs and 
genes. When testing the association between the 2549 
smoking-related CpGs with 443 randomly selected 
gene expression probes, we found that only 325 CpGs 
are associated with at least one of these gene expres-
sion probes and 186 gene expression probes with at least 
one smoking-related CpG. Using the chi-square test of 
independence to compare the use of smoking-related 
gene expression probes versus randomly selected gene 
expression probes, we obtained for the CpGs (1224 vs 
325, respectively) P < 1.0 × 10–5 and for the genes expres-
sion probes (200 vs 186, respectively) a P value of 0.38. 
Similarly, when testing the association between 2549 
randomly selected CpGs with the 443 smoking-related 
gene expression probes, we found only 465 CpGs asso-
ciated with at least one smoking-related gene expres-
sion probe, and 19 gene expression probes with at least 
one smoking-related CpG. Using the chi-square test of 
independence, comparing the use of smoking-related 
CpGs versus randomly selected CpGs, we found a signifi-
cant difference (P < 1.0 × 10–5) for both the CpGs (1224 
vs 465, respectively) and the gene expression probes (200 
vs 19, respectively). These results indicate enrichment of 
smoking-related genes in smoking-related DNA methyla-
tion sites and vice versa.
The replication in the KORA study confirmed the 
association of 134 smoking-related CpGs with at least 
one gene expression probe and 50 smoking-related gene 
expression probes with at least one smoking-related 
CpG, after correcting for multiple testing, at the signifi-
cance threshold of P < 2.04 × 10–7 (0.05/200 × 1224).
Association of smoking‑related changes in DNA 
methylation and gene expression with cardio‑metabolic 
traits
We tested the association of the 1224 CpGs and the 200 
gene expression probes with cardio-metabolic traits, 
Fig. 1 Schematic overview of the study design. In the current paper, previously identified CpGs by the largest available EWAS [6] and genes by the 
largest available TWAS [8] associated with current versus never smokers were used to test the link between smoking and cardio-metabolic traits. To 
this end, we first examined the association between smoking and alterations in gene expression (a). Second, we checked the association between 
the smoking-related CpGs and the smoking-related gene expression probes (a). Third, the smoking-related CpGs and gene expression probes that 
were in eQTM with each other were tested for their association with cardio-metabolic traits (b)
Page 4 of 16Maas et al. Clin Epigenet          (2020) 12:157 
including high-density lipoprotein (HDL), low-density 
lipoprotein (LDL), triglycerides (TG) and serum choles-
terol, fasting glucose and insulin levels, systolic blood 
pressure (SBP) and diastolic blood pressure (DBP), waist 
to hip ratio (WHR) and body mass index (BMI) in the 
Rotterdam Study. After adjusting for age, sex, blood 
cell count, and technical covariates (model 1), we found 
significant associations between 202 out of the 1224 
smoking-related CpGs and any cardio-metabolic trait 
at P < 4.08 × 10–5 (0.05/1224) (n = 1412 participants) 
(Additional file 3: Table S2). Among these, we observed 
associations with HDL (126 CpGs), TG (84 CpGs), glu-
cose (2 CpGs), insulin (10 CpGs), DBP (1 CpG), WHR 
(21 CpGs), and BMI (16 CpGs). After further adjust-
ment for BMI and relevant medication in the model 2, 
associations with 109 CpGs remained significant, includ-
ing HDL (58 CpGs), TG (35 CpGs), DBP (1 CpG), WHR 
(6 CpG), and BMI (16 CpG same as model 1) (Addi-
tional file  3: Table  S3). The R code to test the associa-
tion between cardio-metabolic traits and the CpGs are 
included in Additional file  4. We pursued replication 
in the KORA study for the CpGs reaching significance 
in the model 2 and found that 26 CpGs surpassed the 
nominal significance (P < 0.05, n = 1727 participants), 
including 8 CpGs for HDL, 8 CpGs for TG, 4 CpGs for 
WHR, and 7 CpGs for BMI (Table  2, Additional file  3: 
Table  S3). The direction of associations with cardio-
metabolic traits was consistent in all 26 replicated 
CpGs. Based on the stringent Bonferroni-adjusted P 
value threshold, the replication signals were significant 
at 2 CpGs for TG (P < 0.05/35 = 1.43 × 10–3), 3 CpGs for 
WHR (P < 0.05/6 = 8.33 × 10–3), and 4 CpGs with BMI 
(P < 0.05/16 = 3.13 × 10–3) (Table 2 and Fig. 2).
Furthermore, out of the 200 smoking-related gene 
expression probes 39 (35 genes) were significantly 
associated with at least one cardio-metabolic trait at 
P < 2.5 × 10–4 (0.05/200) in the Rotterdam Study (n = 716 
participants) (Additional file 2: Table S4). In the Illumina 
HumanHT-12 Expression BeadChip array, some of the 
annotated genes have more than one probe. Therefore, 
we adjusted the analysis for the number of probes we 
tested and provided both the probe ID and annotated 
gene in the tables. Of the 39 probes, we found associa-
tions with HDL (15 genes), LDL (1 gene), TG (18 genes), 
cholesterol (1 gene), glucose (3 genes), insulin (13 genes), 
WHR (6 genes), and BMI (14 genes). After further adjust-
ments in model 2, the associations of 29 probes (27 genes) 
remained significant, including HDL (5 genes), LDL (1 
Table 1 Population characteristics
Values are presented as mean ± (SD) or N (%)
BMI body mass index, WHR waist to hip ratio, HDL high-density lipoproteins, LDL low-density lipoprotein
The participants included in the gene expression data are a subset of the total DNA methylation dataset
NA not applicable; the associations with glucose levels in model 2 from the discovery did not pass the significance threshold
Discovery dataset Replication dataset
Gene expression data 
set
DNA methylation data 
set
Gene expression data 
set
DNA 
methylation 
data set
N 716 1412 687 1727
Female 389 (54.3%) 791 (56.0%) 339 (49.3%) 882 (51.0%)
Age (years) 59.8 (± 8.1) 63.6 (± 8.1) 69.1 (± 4.4) 61.0 (± 8.8)
BMI (kg/m2) 27.6 (± 4.6) 27.7 (± 4.4) 28.9 (± 4.5) 28.1 (± 4.8)
WHR 0.9 (± 0.1) 0.9 (± 0.1) 0.9 (± 0.1) 0.9 (± 0.1)
Current smokers 193 (27.0%) 266 (18.0%) 53 (7.7%) 250 (14.5%)
Triglycerides (mmol/L) 1.5 (± 0.9) 1.5 (± 0.8) 1.5 (± 0.9) 1.5 (± 1.1)
HDL-cholesterol (mmol/L) 1.4 (± 0.4) 1.5 (± 0.4) 1.4 (± 0.4) 1.5 (± 0.4)
LDL-cholesterol (mmol/L) 3.9 (± 1.0) 3.8 (± 1.0) 3.7 (± 0.9) 3.6 (± 0.9)
Total cholesterol (mmol/L) 5.6 (± 1.1) 5.5 (± 1.0) 5.8 (± 1.0) 5.7 (± 1.0)
Lipid lowering medication (yes) 190 (26.5%) 404 (28.6%) 172 (25.0%) 283 (16.4%)
Systolic blood pressure (mm Hg) 134.2 (± 19.8) 139.5 (± 21.5) 128.7 (± 19.4) 124.8 (± 18.7)
Diastolic blood pressure (mm Hg) 82.8 (± 11.4) 83.6 (± 11.5) 74.7 (± 10.0) 76.1 (± 10.0)
Anti-hypertensive medication (yes) 215 (30.0%) 517 (36.6%) 383 (55.7%) 650 (37.6%)
Glucose (mmol/L) 5.6 (± 1.0) 5.6 (± 1.1) NA NA
Insulin (pmol/L) 96.0 (± 63.0) 89.3 (± 56.6) 88.2 (± 122.0) 81.3 (± 91.0)
Anti-diabetic medication (yes) 39 (5.4%) 95 (6.7%) 76 (11.1%) 134 (7.8%)
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gene), TG (14 genes), cholesterol (1 gene), and insulin (2 
genes), for the association with BMI nothing changed (14 
genes) (Additional file 3: Table S5). The R code to test the 
association between cardio-metabolic traits and the gene 
expression probes is included in Additional file 5. Repli-
cation in the KORA study for the gene expression probes 
that reached significance in model 2 showed 21 probes 
(19 genes) that passed the nominal significance (P < 0.05, 
n = 687 participants). These include 2 genes for HDL, 13 
genes for TG, 1 gene for insulin, and 10 genes for BMI 
(Table 3, Additional file 3: Table S5). The direction of the 
association between gene expression and cardio-meta-
bolic traits was consistent for all these genes. Based on 
the stringent Bonferroni-adjusted P-value in which we 
adjusted for the number of probes, the replication sig-
nal was significant at 2 genes for HDL (P < 0.05/5 = 0.01), 
11 genes for TG (P < 0.05/15 = 3.33 × 10–3), 1 gene 
for insulin (P < 0.05/2 = 0.025), and 4 genes for BMI 
(P < 0.05/16 = 3.13 × 10–3). Several of these genes 
were associated in model 2 with more than one 
Table 2 CpG sites associated with cardio-metabolic traits in DNA methylation analysis
The table shows 26 CpGs that are associated to at least one cardio-metabolic trait and in eQTM with at least one smoking-related gene-expression probe
Only CpGs significantly associated in both models and nominally significant (P < 0.05) in the replication are presented in this table
HDL high-density lipoprotein, TG triglycerides, WHR waist to hip ratio, BMI body mass index, NA not applicable (because of adjusting for BMI)
Model 1: Adjusted for age, sex, cell count, and technical covariates. Model 2: Model 1 + BMI and relevant medication
We did not correct for additional covariates when testing the association for BMI
P value threshold for discovery P < 4.08 × 10–5 (0.05/1224)
P value threshold for replication: HDL, P < 8.62 × 10–4 (0.05/58); TG, P < 1.43 × 10–3 (0.05/35); WHR, P < 8.33 × 10–3 (0.05/6); BMI, P < 3.13 × 10–3 (0.05/16)
CpGs that are presented underlined passed the replication P value threshold in 1727 participants of the KORA study
a Genome coordinates provided by Illumina (GRCh37/hg19)
b According to the Illumina Infinium HumanMethylation450K annotation file
CpG Chr:positiona Gene  IDb Trait Model 1 Model 2 Replication
Effect P value Effect P value Effect P value
cg04716530 16:30485684 ITGAL HDL 0.01700 2.02E−07 0.01550 6.34E−06 0.00014 9.82E−04
cg07826859 7:45020086 MYO1G HDL 0.01440 6.79E−06 0.01390 3.61E−05 0.00018 1.61E−03
cg26724967 16:3115223 IL32 HDL 0.01290 2.89E−06 0.01220 2.34E−05 0.00015 1.63E−03
cg16391678 16:30485597 ITGAL HDL 0.01520 1.03E−06 0.01400 1.60E−05 0.00013 5.14E−03
cg16519923 16:30485810 ITGAL HDL 0.01980 8.23E−08 0.01790 3.44E−06 0.00012 9.75E−03
cg10310310 7:157367150 PTPRN2;MIR153-2 HDL 0.01130 4.49E−06 0.01060 4.05E−05 0.00011 1.96E−02
cg24323726 3:111314186 ZBED2;CD96 HDL 0.01300 4.84E−07 0.01230 5.32E−06 0.00009 3.41E−02
cg07929642 16:89390685 ANKRD11 HDL 0.01650 1.87E−07 0.01550 3.13E−06 0.00009 4.25E−02
cg21566642 2:233284661 – TG − 0.01990 3.89E−05 − 0.02150 1.91E−05 − 0.01967 1.14E−05
cg04716530 16:30485684 ITGAL TG − 0.01370 1.23E−06 −0.01220 3.58E−05 −0.00380 5.34E−04
cg27409015 2:158114424 GALNT5 TG 0.01660 8.39E−07 0.01490 2.16E−05 0.00683 1.50E−03
cg06635952 2:70025869 ANXA4 TG 0.01300 9.06E−07 0.01280 3.36E−06 0.00502 5.95E−03
cg11095027 11:1297066 TOLLIP TG 0.00996 2.72E−05 0.01040 2.64E−05 0.00375 7.82E−03
cg26219092 8:134388022 – TG 0.01050 2.37E−06 0.00991 2.05E−05 0.00285 1.73E−02
cg10919522 14:74227441 C14orf43 TG − 0.01410 7.90E−09 − 0.01260 7.97E−07 − 0.00491 1.91E−02
cg22635096 21:46550644 ADARB1 TG 0.01370 6.61E−08 0.01300 8.65E−07 0.00392 3.55E−02
cg00310412 15:74724918 SEMA7A WHR − 0.05000 3.96E−05 − 0.07150 1.95E−07 − 0.06952 4.54E−05
cg04424621 6:27101941 HIST1H2BJ WHR − 0.06490 1.06E−05 − 0.07360 1.03E−05 − 0.07191 5.73E−05
cg04583842 16:88103117 BANP WHR 0.12600 5.29E−08 0.12500 1.56E−06 0.06802 3.71E−03
cg13755776 11:3602845 – WHR − 0.08530 1.03E−06 − 0.08200 3.33E−05 − 0.04521 3.71E−02
cg17287155 5:393347 AHRR BMI 0.00117 8.69E−06 NA NA 0.00053 3.11E−06
cg26361535 8:144576604 ZC3H3 BMI 0.00155 1.85E−07 NA NA 0.00102 2.38E−05
cg06096336 2:231989800 PSMD1;HTR2B BMI 0.00168 9.51E−07 NA NA 0.00111 1.66E−04
cg13708645 12:121974305 KDM2B BMI 0.00152 6.72E−07 NA NA 0.00089 1.01E−03
cg25649826 17:20938740 USP22 BMI 0.00086 1.63E−05 NA NA 0.00041 3.15E−03
cg24539517 10:121161258 GRK5 BMI 0.00149 2.95E−05 NA NA 0.00078 4.33E-03
cg03636183 19:17000585 F2RL3 BMI 0.00160 3.04E−05 NA NA 0.00063 3.40E−02
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cardio-metabolic trait and were replicated at least at 
the nominal significance (P < 0.05). For example, KLRB1 
(ILMN_2079655), ITM2C (ILMN_2366041), and CD3D 
(ILMN_2261416) were associated with both TG and 
BMI, and OCIAD2 (ILMN_1700306) was associated with 
both HDL and TG, and EFHD2 (ILMN_1761463) was 
associated with HDL, TG, and BMI (Table 3 and Fig. 2).
Next, we explored whether there is an overlap in the 
results obtained with DNA methylation and gene expres-
sion data, which possibly explain the link between smok-
ing and cardio-metabolic traits. Table 4 shows the overlap 
of the replicated association of cardio-metabolic traits 
with gene expression, which were both also associated 
with the smoking-related CpGs, indicating a three-way 
association (Fig. 1). Additional file 3: Table S6 displays the 
three-way association as obtained in our discovery data-
set. For example, we found in the Rotterdam Study over-
lapping association of serum HDL levels with four CpGs 
(cg01305745, cg06177555, cg07990556, and cg16448702) 
and expression levels of three genes (EFHD2, PRF1, and 
OSBPL5). Likewise, we found the association of TG lev-
els with 18 CpGs and six genes (ICOS, GZMA, C12orf57, 
CD3D, CLDND1, and EFHD2). Finally, we found BMI 
to be associated with 16 CpGs and five genes (LRRN3, 
EFHD2, PID1, STOM, and CD3D) (Additional file  3: 
Table S6). Of these, we were able to replicate the three-
way association of TG with DNA methylation levels of 
cg04716530 and expression levels of GZMA, and DNA 
Fig. 2 The overlap of smoking-related CpGs and genes in association with cardio-metabolic traits. In the current study, 2549 smoking-related CpGs 
and 443 smoking-related gene expression probes were included. Of these, 1224 CpGs and 200 gene expression probes showed eQTM association. 
We found the association for 26 CpGs and 19 genes (21 expression probes) with at least one cardio-metabolic traits, which surpassing the nominal 
significance (P < 0.05) in the KORA replication study
Page 7 of 16Maas et al. Clin Epigenet          (2020) 12:157  
methylation levels of cg21566642 and expression levels 
of CLDND1 in the KORA study. Furthermore, we found 
BMI to be associated with DNA methylation levels of 6 
CpGs and expression of two genes (LRRN3 and PID1) 
(Table 4).
In the three-way association (Table 4), we also iden-
tified CpGs associated with expression levels of genes 
far approximate from their annotated gene/loci. We did 
a lookup for the identified CpGs for eQTM association 
using data from the BIOS-BBMRI database (https 
://www.genen etwor k.nl/biosq tlbro wser/). Here, we 
found cis-eQTMs between cg17287155 and expres-
sion of EXOC3 and between cg03636183 and expres-
sion of F2RL3. In the Rotterdam Study, both EXOC3 
and F2RL3 gene expression probes did not pass the QC. 
Hence, we could not test the influence of these genes 
in the identified eQTM associations in a three-way 
analysis.
Table 3 Gene expression probes associated with cardio-metabolic traits
The table shows 21 probes annotated to 19 genes that are significantly associated with cardio-metabolic traits and in eQTM with at least one smoking-related CpG
Only probes significantly associated in both models and nominally significant (P < 0.05) in the replication are presented in this table
HDL high-density lipoprotein, TG triglycerides, BMI body mass index, NA not applicable (because of adjusting for BMI)
Model 1: Adjusted for age, sex, cell count, RNA quality score, and technical covariates. Model 2: Model 1 + BMI and relevant medication
We did not correct for additional covariates when testing the association for BMI
P value threshold P < 2.25 × 10–4 (0.05/200)
P value threshold for replication: HDL, P < 0.01, (0.05/5); TG, P < 3.33 × 10–3 (0.05/15); Insulin, P < 0.03 (0.05/2); BMI, P < 3.13 × 10–3 (0.05/16)
Genes that are presented underlined passed the replication p value threshold in 687 participants of the KORA study
a According to the by Illumina provided annotation file
Probe ID Gene  IDa Chr. a Trait Model 1 Model 2 Replication
Effect P value Effect P value Effect P value
ILMN_1700306 OCIAD2 4 HDL − 0.4114 8.39E−07 − 0.3573 5.15E−05 − 0.0040 9.20E−05
ILMN_1761463 EFHD2 1 HDL 0.4668 1.60E−07 0.3576 0.00013 0.0022 1.38E−03
ILMN_2261416 CD3D 11 TG 0.9089 2.22E−15 0.8328 3.84E−12 0.3233 2.58E−15
ILMN_2079655 KLRB1 12 TG 1.1666 6.48E−14 1.0518 1.01E−10 0.3946 4.09E−15
ILMN_1779324 GZMA 5 TG 1.0562 1.99E−09 1.0033 6.01E−08 0.2734 2.06E−13
ILMN_1761463 EFHD2 1 TG − 0.4238 2.59E−09 − 0.3434 3.54E−06 − 0.1298 9.99E−13
ILMN_1700306 OCIAD2 4 TG 0.3413 3.32E−07 0.2998 1.93E−05 0.1691 7.64E−10
ILMN_1808939 RPS6 9 TG 0.6145 5.58E−11 0.5687 7.54E− 09 0.3001 1.17E−09
ILMN_1812191 C12orf57 12 TG 0.4392 1.37E−05 0.3897 0.00023 0.1772 1.07E−07
ILMN_1776181 BIRC3 11 TG 0.6940 2.86E−10 0.6176 8.34E−08 0.1473 4.89E−07
ILMN_1813836 DARS 2 TG 0.2657 9.37E−07 0.2878 4.67E−07 0.0894 3.18E-06
ILMN_1669927 ICOS 2 TG 0.2859 6.88E-06 0.2692 5.75E-05 0.0925 2.95E−04
ILMN_2198878 INPP4B 4 TG 0.2950 2.99E−07 0.2853 2.53E−06 0.0668 5.93E−04
ILMN_2366041 ITM2C 2 TG − 0.5648 6.81E−09 − 0.4159 3.35E−05 − 0.0818 6.33E−03
ILMN_1680453 ITM2C 2 TG − 0.5880 5.50E−08 − 0.4295 0.000124 − 0.0818 7.05E−03
ILMN_2352563 CLDND1 3 TG 0.3877 4.61E−05 0.4003 6.52E−05 0.0656 3.53E−02
ILMN_2079655 KLRB1 12 Insulin 0.7694 7.01E−09 0.6393 5.21E−05 0.2120 5.59E−05
ILMN_1766657 STOM 9 BMI 0.0549 3.85E−07 NA NA 0.0196 2.56E−08
ILMN_1671891 PID1 2 BMI − 0.0425 7.23E−09 NA NA − 0.0137 3.27E−06
ILMN_2366041 ITM2C 2 BMI − 0.0577 1.86E−09 NA NA − 0.0123 9.53E−05
ILMN_1773650 LRRN3 7 BMI − 0.0669 3.77E−05 NA NA − 0.0162 1.70E−03
ILMN_1661599 DDIT4 10 BMI − 0.0658 2.75E−07 NA NA − 0.0096 4.06E−03
ILMN_2048591 LRRN3 7 BMI − 0.0604 1.46E−05 NA NA − 0.0086 6.95E−03
ILMN_2377669 CD247 1 BMI − 0.0370 5.95E−05 NA NA − 0.0058 8.01E−03
ILMN_2109197 EPB41L3 18 BMI − 0.0322 0.000112 NA NA − 0.0072 1.12E−02
ILMN_2261416 CD3D 11 BMI 0.0458 6.47E−05 NA NA 0.0107 1.37E−02
ILMN_2079655 KLRB1 12 BMI 0.0669 1.63E−05 NA NA 0.0122 2.29E–−02
ILMN_1761463 EFHD2 1 BMI − 0.0339 1.46E−06 NA NA − 0.0038 4.68E−02
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Mediation analysis for smoking‑related CpGs and genes 
associated with cardio‑metabolic traits
As shown in Fig. 3, we used mediation analysis to investi-
gate the effect of DNA methylation and gene expression, 
independently, in the association between smoking and 
cardio-metabolic traits. Also, we tested the mediating 
effect of DNA methylation in the association between 
smoking and gene expression. In total, we conducted 
three different models; first, gene expression as a media-
tor in the observed association between smoking and car-
dio-metabolic traits (A1 and A2 in Fig. 3); second, DNA 
methylation as a mediator in the observed association 
Table 4 The DNA methylation sites associated with gene
The table shows an overview of the overlap of the hits with nominal significant (P < 0.05) replication in KORA in all three association analyses, including the association 
between (1) DNA methylation and cardio-metabolic traits, (2) gene expression and cardio-metabolic traits, and (3) the eQTM results for the gene and CpG that are 
associated with the same cardio-metabolic trait
P value thresholds in the discovery for DNA methylation P < 4.08 × 10–5 (0.05/1224), gene expression P < 2.25 × 10–4 (0.05/200) and for eQTM P < 4.4 × 10–8 
(0.05/443 × 2549)
P value thresholds in the replication for TG; gene expression P < 3.33 × 10–3 (0.05/15), DNA methylation P < 1.43 × 10–3 (0.05/35), and BMI; gene expression
P < 3.13 × 10–3 (0.05/16), DNA methylation P < 3.13 × 10–3 (0.05/16), and eQTM P < 2.04 × 10–7 (0.05/1224 × 200)
Results that are presented underlined passed the replication P value threshold in the KORA study
TG triglycerides, BMI body mass index
a Expression probe ~ cardio-metabolic trait + age, sex, cell count, RNA quality score, technical covariates, BMI and relevant medication
b CpGs ~ cardio-metabolic trait + age, sex, cell count, technical covariates, BMI and relevant medication
c Expression probe ~ CpGs + age, sex
Gene  expressiona Trait DNA  methylationb eQTMc
ProbeID Effect P value CpG Effect P value Coeff P value
ILMN_1779324 (GZMA) 1.0033 6.01E−08 TG cg04716530 − 0.0122 3.58E−05 − 11.7641 6.91E−12
ILMN_2352563 (CLDND1) 0.4003 6.52E−05 TG cg21566642 − 0.0215 1.91E−05 − 5.1957 3.54E−19
ILMN_1671891 (PID1) − 0.0425 7.23E−09 BMI cg03636183 0.0016 3.04E−05 − 3.9797 1.28E−11
ILMN_1773650 (LRRN3) − 0.0669 3.77E−05 BMI cg03636183 0.0016 3.04E−05 − 16.4622 3.46E−41
cg06096336 0.0017 9.51E−07 − 15.0031 2.91E−24
cg13708645 0.0015 6.72E−07 − 9.5025 2.31E−09
cg17287155 0.0012 8.69E−06 − 26.2306 3.09E−54
cg25649826 0.0009 1.63E−05 − 14.4989 3.43E−08
cg26361535 0.0016 1.85E−07 − 12.549 2.30E - 11
ILMN_2048591 ( LRRN3) − 0.0604 1.46E−05 BMI cg03636183 0.0016 3.04E−05 − 14.4435 2.67E−43
cg06096336 0.0017 9.51E−07 − 11.5428 1.40E−19
cg13708645 0.0015 6.72E−07 − 8.2627 1.36E−09
cg17287155 0.0012 8.69E−06 − 21.4408 1.19E−48
Fig. 3 Schematic overview of the mediation analyses. We used mediation analysis to test the mediation effect of gene expression in the association 
between smoking and cardio-metabolic traits (A1 and A2). Furthermore, we tested the mediation effect of DNA methylation in the associations 
between smoking and gene expression (B1 and B2) and the mediation effect of DNA methylation in the association between smoking and 
cardio-metabolic traits (C1 and C2)
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between smoking and gene expression (B1 and B2 in 
Fig.  3); and third, DNA methylation as the mediator in 
the association between smoking and cardio-metabolic 
traits (C1 and C2 in Fig.  3). We conducted the average 
causal mediation effect (ACME), average direct effect 
(ADE), and the proportion mediated (Prop. med.), which 
are illustrated in Table 5 (and Additional file 3: Table S7). 
The ADE reflects the effect of smoking on the tested out-
come that does not depend on the mediator. The R code 
for the mediation analyses is included in Additional file 6, 
and an example input file is provided in Additional file 7.
The mediation effect of the three-way associations 
as obtained in our discovery dataset (Additional file  3: 
Table S6) is provided in Additional file 3: Table S7. Out 
of the 124 mediation analysis conducted, there was sig-
nificant mediation effect in 69 of them in the Rotterdam 
Study (Additional file  3: Table  S7). Of these, we were 
able to replicate the mediating effect of cg01305745 
(VKORC1) and cg16448702 (INPP5D) in the association 
between smoking and PRF1 expression (ILMN_1740633). 
Also, we identified the mediating effect of cg16448702 
(INPP5D) in the association between smoking and 
OSBPL5 (ILMN_1802151). Furthermore, we replicated 
the mediation effect of 9 CpGs in the association between 
smoking and LRRN3 expression (ILMN_1773650 and 
ILMN_2048591) (Additional file  3: Table  S7). Finally, 
of the replicated three-way associations as shown in 
Table  4, we were able to replicate the mediation effect 
of cg03636183 (F2RL3), cg06096336 (PSMD1; HTR2B), 
cg13708645 (KDM2B), and cg17287155 (AHRR) in the 
association between smoking and LRRN3 expression 
(Table  5). We conducted the ρ at which ACME is 0, to 
test the models’ sensitivity. Here, we obtained ρ’s in the 
range between − 0.1 and − 0.5, and 0.1 and 0.4. A value 
of ρ close to 0 indicates that the assumption we made is 
sensitive to violations [24].
Discussion
The associations of smoking, gene expression, and DNA 
methylation with cardio-metabolic traits have been 
studied independently and reviewed in great detail [11, 
25–28]; however, the overlap between epigenetics and 
transcriptomics in the association between smoking and 
cardio-metabolic traits has been studied much less. This 
study investigated the relationship between previously 
identified smoking-related changes in DNA methylation 
[6] and gene expression [8], followed by their associa-
tions with cardio-metabolic traits within two population-
based cohort studies. In this line, we first showed several 
significant cis- and trans-eQTM associations between 
smoking-related CpGs and gene expression probes. Fur-
thermore, we replicated 26 smoking-related CpGs and 
19 smoking-related genes (21 probes) associated with 
cardio-metabolic traits. Moreover, we showed three-
way association of TG with two CpGs and two genes 
(GZMA and CLDND1), and BMI with six CpGs and two 
genes (PID1 and LRRN). Finally, our study demonstrated 
a mediating effect of 4 CpGs (cg03636183, cg06096336, 
cg13708645, and cg17287155) in the association between 
smoking and the BMI-related gene LRRN3.
Our results showed a three-way association between 
TG with the decrease in DNA methylation levels of 
cg21566642 and the increase in expression levels of 
CLDND1. In this line, smoking was associated with an 
increase in the expression of CLDND1 [8] and a decrease 
in cg21566642 DNA methylation levels [6]; and here, we 
Table 5 Mediation effect of  DNA methylation and  gene expression in  the  association between  smoking and  cardio-
metabolic traits
The table shows the results of mediation analysis, in which current smoking is always used as exposure and is adjusted for age and sex
ACME average causal mediation effect, ADE average direct effect, Prop. Med proportion mediated
a ρ at which ACME is 0 indicates how sensitive our model is to the non-unmeasured confounding assumption
Mediator Outcome ACME (95% CI) ADE (95% CI) Total effect (95% 
CI)
Prob. Med. (95% CI) ρ at which 
ACME is  0a
cg03636183 (F2RL3) ILMN_1773650 
(LRRN3)
0.6835 
(0.4731/0.8869)
1.9603 
(1.5832/2.3822)
2.6438 
(2.2907/3.0048)
0.2585 
(0.1767/0.3432)
− 0.3
cg06096336 
(PSMD1;HTR2B)
ILMN_1773650 
(LRRN3)
0.1237 
(0.0263/0.2396)
2.5202 (2.1796/2.849) 2.6438 
(2.2907/3.0048)
0.0468 
(0.0102/0.0886)
− 0.4
cg13708645 (KDM2B) ILMN_1773650 
(LRRN3)
0.0768 (0.025/0.1408) 2.5671 
(2.2153/2.9309)
2.6438 
(2.2907/3.0048)
0.0290 
(0.0092/0.0533)
− 0.1
cg17287155 (AHRR) ILMN_1773650 
(LRRN3)
0.6357 
(0.4798/0.8094)
2.0081 (1.6771/2.333) 2.6438 
(2.2907/3.0048)
0.2405 
(0.1835/0.3036)
− 0.5
cg06096336 
(PSMD1;HTR2B)
ILMN_2048591 
(LRRN3)
0.0992 
(0.0198/0.1915)
2.2838 
(1.9578/2.5975)
2.3830 (2.0445/2.721) 0.0416 
(0.0085/0.0779)
− 0.3
cg17287155 (AHRR) ILMN_2048591 
(LRRN3)
0.5004 
(0.3828/0.6542)
1.8826 
(1.5691/2.2123)
2.3830 (2.0445/2.721) 0.2100 
(0.1603/0.2724)
− 0.4
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showed the inverse relation between CLDND1 expres-
sion and methylation levels at cg21566642. The expres-
sion of CLDND1, a tight junction protein, is shown to 
be highly increased in human Colon cancer samples 
and cell lines, and also positively correlated with tumor 
growth and disease progression [29]. The inverse associa-
tion between DNA methylation levels at cg21566642 and 
smoking was previously shown in blood samples with 
cross-tissue replications in adipose tissue and skin tis-
sue [20]. Additionally, cg21566642 is inversely associated 
with CVD risk [30], all-cause mortality [31], and with left 
ventricular mass (LVM) index in young adults [32]. LVM 
index is an important cardiac remodeling trait that is an 
intermediate phenotype for heart failure. In line with 
this, an increased LVM index is associated with high lev-
els of TG [33, 34] and with an increased risk of depressed 
left ventricular ejection fraction, coronary heart disease, 
congestive heart failure, and stroke [35, 36].
In the three-way association for BMI, we found that 
smoking is associated with lower BMI, indicating that 
current smokers are less likely to be obese than never 
smoker, which has been reported in several previ-
ous studies as well [37–39]. Our results further showed 
that cg03636183 (F2RL3) was positively associated 
with BMI and negatively associated with the expres-
sion of PID1 and LRRN3. Smoking was inversely associ-
ated with cg03636183 [6] and positively with PID1 and 
LRRN3 expression [8]. Here, we found an inverse relation 
between cg03636183 and expression levels of PID1 and 
LRRN3. Due to the quality control implemented within 
the Rotterdam Study gene expression profiling data, gene 
expression data on F2RL3 was not available. Therefore, 
we could not test if the association of cg03636183 with 
PID1 and LRRN3 expression levels was independent or 
via a downstream effect of F2RL3 expression. Nonethe-
less, the inverse correlation between DNA methylation 
levels at cg03636183 and expression of F2RL3 was pre-
viously shown [20]. This might indicate that the identi-
fied eQTM associations are, at least partly, via F2RL3 
expression. F2RL3 encodes the protease-activated recep-
tor-4 (PAR-4), a protein expressed in various tissues 
that introduce platelet activation, intimal hyperplasia, 
and inflammation [40]. Furthermore, the expression of 
F2RL3 was associated with metabolic disease risk phe-
notypes, including a negative association with visceral 
fat mass and a positive association with total fat mass 
and android-to-gynoid fat ratio [20]. Additionally, the 
inverse association between DNA methylation levels at 
cg03636183 and smoking has been shown in blood sam-
ples with cross-tissue replications in adipose and skin 
tissues [20]. The inverse relation between DNA methyla-
tion levels at cg03636183 and TG [41], all-cause mortality 
[31], lung cancer incidence and mortality [42], as well as 
total mortality and cardiovascular mortality [43] was also 
previously identified. Also, a smoking-related decrease in 
cg03636183 methylation levels appears to increase serum 
levels of IL-18 [44]. IL-18 promotes the synthesis of IL-6, 
which stimulates the production of serum CRP [45, 46]. 
The increase in IL-18 and IL-6 leads to a higher risk ratio 
for CHD development [47]. Moreover, the increase in 
serum CRP concentrations results in increased risk ratios 
for CHD, ischemic stroke, vascular mortality, and non-
vascular mortality [48].
Two of the CpGs, cg26361535 (ZC3H3) and 
cg25649826 (USP22), for which we found a three-way 
association with BMI and LRRN3, have been reported 
to be positively associated with BMI [49]. Both CpGs are 
cross-tissue replicated in adipose tissue and in isolated 
adipocytes for obese cases versus normal-weight con-
trols. The association with cg26361535 was in the same 
direction and for cg25649826 in the opposite direction 
as obtained in our results [49]. Additionally, both CpGs 
were positively associated in blood with weight, WHR, 
glucose, insulin, TG, and CRP, and negatively with HDL. 
Furthermore, cg26361535 was positively associated with 
SBP and DBP [49] and all-cause mortality [31].
Finally, we identified a three-way association between 
BMI, an increase in methylation levels at cg17287155 
(AHRR), and LRRN3 expression. Smoking is negatively 
associated with DNA methylation levels at cg17287155 
[6] and, as we replicated here, positively associated with 
BMI [50]. Notably, in the eQTM look-up we found a cis-
eQTM for cg17287155 with the expression of EXOC3, 
instead of with its annotated gene (AHRR). AHRR is a 
well-studied gene in relation to smoking [5] and is a key 
regulator of the Xenobiotic metabolism pathway respon-
sible for detoxification of polyaromatic hydrocarbons 
(PAHs) in tobacco smoke [51, 52]. Nevertheless, EXOC3 
overexpression increases insulin-induced glucose uptake 
in adipocytes [53], indicating a possible link for EXOC3 
with CVD-related risk factors. Further research is needed 
to verify the eQTM-associations for cg17287155 with 
EXOC3 and its impact on the eQTM-associations identi-
fied in the current study.
The identified associations and mediating effects in 
our study indicate a possible regulatory effect of DNA 
methylation on the expression levels of genes far from 
the neighboring methylation site, which so-called trans-
regulatory effect of methylated CpG sites on gene expres-
sion [54]. So far, most previous studies have limited their 
research to the correlation between gene expression and 
DNA methylation at CpGs located in the nearby regions 
and in the gene body, or the cis-regulatory effect. In 
this line, a recent study has shown the trans-regulatory 
effect of DNA methylation in the associations with gene 
expression and chronic obstructive pulmonary disease 
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[54]. Therefore, future research is needed with a broader 
methodological approach, including examining possible 
trans-regulatory effects to gain more insight into the epi-
genetic regulatory effects in disease studies.
This study has strengths as well as limitations that 
should be considered when interpreting the results. 
The main strengths of this study include the availabil-
ity of DNA methylation data in a large sample of adults 
from the general population overlapping with transcrip-
tomic and clinical data. Another strength is the use of 
the largest available EWAS [6] and TWAS [8] to date for 
selecting the CpGs and genes of interest associated with 
smoking. A limitation of the current study could be that 
data on smoking habits are retrieved from question-
naires, which might be underestimating actual smoking 
levels possibly leading to information bias [55–57]. This 
self-reporting bias can arise due to several reasons, such 
as recall bias in which a participant might not remember 
the true exposure or social desirability bias in which par-
ticipants deliberately underestimate due to the socially 
stigmatized nature [57]. However, we expect the under-
estimation to be primarily quantitative and should not 
significantly impact the current versus non-smoker cate-
gorization we used in this study. Also, the questionnaires 
used for smoking data-collection did not include infor-
mation regarding passive smoking, which is a risk fac-
tor for CVD [58]. As a result, we were not able to adjust 
for the passive-smoking effect in our analysis. As these 
participants are included in the non-smoker group, this 
might have underestimated the true effect.
Furthermore, due to the nature of the current study 
we have included the same participants in all mediation 
analyses and have used the mediator and exposure meas-
urements on the same time-point; therefore, we can-
not rule out reverse causality. Another limitation is that 
DNA methylation and gene expression levels were only 
measured at baseline; hence, we have no access to pre-
measurement covariates. Consequently, we could not 
further adjust our models without risking the adjustment 
of a mediator, which could explain the ρ values close to 0 
we obtained in a subset of our models in the sensitivity 
analysis. However, we did include additional adjustments 
(e.g., BMI and relevant medication) in the association 
analysis between cardio-metabolic traits with DNA 
methylation and gene expression, indicating the robust-
ness of the identified three-way associations. Also, due to 
the stringent quality control in the Rotterdam Study, we 
were not able to test the impact of the cis-eQTM genes 
in the identified eQTMs. Finally, the use of whole-blood 
for the quantification of DNA methylation and transcrip-
tomics associated with smoking and cardio-metabolic 
traits could be a limitation, since DNA methylation and 
gene expression are tissue-specific. Nonetheless, these 
data from other tissues are currently not available in the 
majority of population-based studies including the two 
participating cohorts in this study.
Conclusions
In this study, we tested the association of smoking-
related changes in DNA methylation and gene expres-
sion with cardio-metabolic traits. We found a three-way 
association of TG and BMI with CVD-relevant CpG 
sites and genes. Our results may provide further insight 
into the possible molecular cascades linking smoking to 
metabolic risk factors leading to CVD. Further research 
is warranted to conduct experimental research on the 
molecular mechanisms of the impact of smoking on car-
diovascular disease and its risk factors through changes 
in DNA methylation and gene expression levels.
Methods
Study population
The discovery data set comprised a total of 1412 par-
ticipants included in the Rotterdam Study; the design 
from the Rotterdam Study has been described elsewhere 
[21]. Briefly, in 1990 all residents of Ommoord, a district 
in Rotterdam, aged 55  years and older, were invited for 
participation (RS-I). In 2000, the cohort was extended 
with participants who had reached the age of 55 years or 
who had moved into the district (RS-II). An additional 
group was invited in 2006, from the age of 45 years and 
older (RS-III). Participants have been re-examined every 
3–4  years. In the current study, we used data from the 
third visit from RS-II (RS-II-3) and the first and second 
visit of RS-III (RS-III-1 and RS-III-2). In total, DNA 
methylation measurements of 1412 participants from RS-
III-1, RS-II-3, and RS-III-2 were included in our analysis. 
Additionally, gene expression data were available for 716 
participants included in RS-III-1. Smoking information 
was collected via self-reported questionnaires; additional 
data collection details are described in Additional file 8.
The replication data comprised a total of 1717 par-
ticipants included in The Cooperative Health Research 
in the Region of Augsburg (KORA) study. The KORA 
study is a series of independent population-based epi-
demiological surveys and follow-up studies of par-
ticipants living in the region of Augsburg, Southern 
Germany. The KORA F4 study, a 7-year follow-up study 
of the KORA S4 survey (examined 1999–2001), was 
conducted between 2006 and 2008. The standardized 
examinations applied in the survey have been described 
in detail elsewhere [21]. A total of 3080 subjects with 
ages ranging from 32 to 81  years participated in the 
examination. In a random subgroup of 1802 KORA 
F4 subjects, the genome-wide DNA methylation pat-
terns were analyzed as described in Additional file  3. 
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Smoking information was collected via self-reported 
questionnaires; additional data collection details are 
described in Additional file 8.
DNA methylation data
DNA methylation in the Rotterdam Study and KORA 
study was extracted from whole peripheral blood and 
DNA methylation measurements were obtained using 
the Illumina Infinium Human Methylation 450K Bead-
Chip (Illumina Inc, San Diego, CA, USA). The DNA 
methylation pre-processing procedures are described in 
Additional file  3. The methylation proportion of a CpG 
site was reported as a methylation β-value in the range 
of 0 to 1. Genome coordinates provided by Illumina 
(GRCh37/hg19) were used to identify independent loci.
In the current study, CpGs of interest were selected 
using a recent EWAS [6] investigating the association 
between tobacco smoking and changes in DNA meth-
ylation values in the epigenome. In total, 2623 CpG sites 
were identified as being significantly (P < 1 × 10–7) differ-
entially methylated between smokers and never smok-
ers. In the Rotterdam Study, 2549 out of the 2623 CpGs 
passed the quality control and are included in this study 
(Additional file 3: Table S8).
RNA expression data
In the Rotterdam Study, RNA was isolated from whole 
blood and gene expression profiling was performed using 
the IlluminaHumanHT-12v4 Expression Beadchips (Illu-
mina, San Diego, CA, USA). The expression dataset is 
available at Gene Expression Omnibus (GEO) public 
repository under the accession GSE33828: 881 samples 
are available for analysis. In KORA F4, total RNA was 
extracted from whole blood and the Illumina Human 
HT-12 v3 Expression BeadChip (Illumina, San Diego, 
CA, USA) was used for gene expression profiling [59]. A 
more detailed description is implemented in Additional 
file 8.
In the current study, genes of interest were selected 
using a previous TWAS testing the association between 
gene expression and current versus never-smoking status 
[8]. In this TWAS, the meta-analysis was performed on 
all transcripts with matching gene Entrez IDs. Employ-
ing a significance threshold of FDR < 0.05, 886 significant 
gene Entrez IDs were identified, of which 387 replicated 
in an independent dataset. Employing the annotation file 
provided by the Illumina (HumanHT-12_V4), we found 
502 gene expression probes to be annotated to these gene 
Entrez IDs out of which 443 were present in the Rotter-
dam Study and were included in the current study (Addi-
tional file 8: Table S9).
Correlation between DNA methylation and gene 
expression
Since DNA methylation and gene expression may affect 
each other (i.e., eQTMs), we tested the association 
between 2549 CpGs and 443 gene expression probes 
linked to smoking in participants who had both meth-
ylation and gene expression data available in the Rotter-
dam Study (N = 716). We regressed out age, sex, blood 
cell counts (fixed effect), and technical covariates (ran-
dom effect) on the normalized beta-values of the CpGs 
and separately on the mRNA expression levels using a 
linear mixed model analysis. The association between 
the residuals of DNA methylation (independent vari-
able) and gene expression (dependent variable) was 
examined using a linear regression model. The robust 
Bonferroni-corrected P value threshold for a significant 
association was P < 4.4 × 10–8 (0.05/443 × 2549).
Additionally, we randomly selected 443 gene expres-
sion probes from the IlluminaHumanHT12v4 Expres-
sion Beadchips, and 2549 CpGs from the Illumina 
Human 450K array, that were available in the Rotter-
dam Study. Using the same methods mentioned above, 
we tested the association between the 2549 smoking-
related CpGs with the 443 randomly selected gene 
expression probes, and the association between 2549 
randomly selected CpGs with the 443 smoking-asso-
ciated gene expression probes. The chi-square test of 
independence was used to test possible enrichment for 
the smoking effect.
Association of DNA methylation and gene expression 
with cardio‑metabolic traits
We studied the relationship of cardio-metabolic traits 
with (1) smoking-CpGs associated with at least one 
smoking-gene probe, and (2) smoking-gene probes asso-
ciated with at least one smoking-CpG. We included the 
following cardio-metabolic-related phenotypes: HDL, 
LDL, TG, serum cholesterol, fasting glucose and insulin 
levels, SBP, DBP, WHR, and BMI.
First, we tested the association between the smoking-
related CpGs (dependent variable) with the cardio-meta-
bolic traits (exposure variable) using linear mixed effects 
models (LME4 package in R). The selected covariates in 
model 1 with fixed effects were age, sex, and cell counts 
for granulocytes, lymphocytes and monocytes. Array 
number and position number on array were added in 
the model as covariates with random effect to correct 
for batch effect. In model 2, we additionally adjusted for 
BMI and relevant medication, including for lipid expo-
sures (lipid-lowering medication), for glycemic traits 
(glucose-lowering medication), for SBP and DBP (lipid-
lowering medication and anti-hypertensives, diuretics, 
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beta-blockers, calcium channel blockers, and RAAS 
modifying agents).
Second, we tested the association between gene expres-
sion (dependent variable) and the cardio-metabolic traits 
(exposure variable) using linear mixed-effects models 
(LME4 package in R), adjusting for age, sex, blood cell 
counts (granulocytes, lymphocytes, and monocytes), 
RNA quality score and batch effect. In model 2, we addi-
tionally adjusted for BMI and relevant medication (as 
described for DNA methylation).
Third, we combined our EWAS and TWAS results and 
showed the obtained three-way association; CpG versus 
gene expression; cardio-metabolic trait versus CpG; car-
dio-metabolic trait versus gene expression. For the CpG 
versus gene expression, we did a lookup for the identified 
CpGs to identify possible cis- eQTM associations using 
data from five Dutch biobanks (BIOS-BBMRI database) 
in a total of 3841 whole blood samples (https ://www.
genen etwor k.nl/biosq tlbro wser/).
Mediation analysis
CpGs and gene expression probes associated with each 
other and associated with the same cardio-metabolic 
trait were reviewed in three mediation analyses (Fig. 3); 
(1) the mediation of gene expression in the association 
between smoking status and the cardio-metabolic trait, 
(2) the mediation of DNA methylation in the association 
between smoking status and gene expression changes, 
and (3) the mediation of DNA methylation in the asso-
ciation between smoking status and the cardio-metabolic 
trait. In all three analyses, we included the same partici-
pants, current versus non-smokers as exposure and all 
models are corrected for age and sex. In the first analy-
sis, we used the gene expression as potential mediator 
and the cardio-metabolic trait as outcome. In the second 
analysis, we used DNA methylation as possible media-
tor and the gene expression as outcome. In the third 
analysis, we used DNA methylation as possible mediator 
and the cardio-metabolic trait as outcome. We used the 
“mediate” function in the mediation package in R [60], 
using the bootstrap method including 1000 simulations 
and confidence intervals using the BCa method [61]. 
The proportion mediated describes the average magni-
tude of indirect association between smoking status and 
the gene expression or cardio-metabolic trait attributed 
through changes in DNA methylation or gene expression 
relative to the average total association, and it is calcu-
lated by dividing the average causal mediation effect by 
the average total effect [62]. Asymptotic 95% confidence 
intervals (CI) were obtained from nonparametric boot-
strapping with 1000 iterations. These mediation analy-
ses assumed no additional unmeasured confounding; 
however, if unobserved variables confound the models, 
the unmeasured confounding assumption is violated. 
Therefore, we used the sensitivity analysis included in the 
mediation package using the “medsens” function con-
ducted by varying the values of ρ and determine the ρ at 
which ACME is 0 per model. Obtaining a value of ρ close 
to 0 indicates that the assumption is sensitive to viola-
tions, meaning that having a confounder with a higher 
correlation than the value of ρ, the assumption of no 
additional unmeasured confounding likely does not hold 
[24].
Replication in the KORA study
The identified associations in the Rotterdam Study were 
replicated using the same models in the KORA study. 
The adjustment for blood cell counts (monocytes, gran-
ulocytes, and lymphocytes) was based on Houseman 
estimates rather than laboratory measurements [63]. Fur-
thermore, principal components were used to adjust for 
technical covariates rather than plate number and posi-
tion on array.
Statistical analysis
All analyses were performed using the statistical pack-
age R. The eQTM analysis, and the associations of the 
cardio-metabolic traits with smoking-related CpGs and 
genes were conducted in R (version 3.2.0) under a Linux 
operating system, using the “LME4” package (version 
1.1-16) and the “parallel” package (version 3.2.0). The 
mediation analyses were conducted in R studio Desktop 
(version 3.2.0) under Windows operating system using 
the “mediation” package (version 4.4.6.). Data collection 
and related statistical methods are provided in Additional 
file 8.
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Additional file 1. In Additional file 1 (Table S1), we show the expression 
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Additional file 4. In Additional file 4, we provided the R code we used 
for testing the association between the smoking-related CpGs and the 
cardio-metabolic traits.
Additional file 5. In Additional file 5, we provided the R code we used 
for testing the association between the smoking-related gene expression 
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